Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $0.15, $0.45 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $71 million versus the consensus estimate of $69.07 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2024 EPS of ~($0.30), versus the consensus of ($0.92). Fulgent Genetics, Inc. sees FY2024 revenue of ~$280 million, versus the consensus of $280 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.